Monkeypox is a rare viral zoonotic disease—a disease transmitted from animals to humans. The virus that causes monkeypox is a member of the same virus family (genus: “Orthopoxvirus”) as the virus that causes smallpox (variola). Monkeypox is characterized by fever, malaise, and the progressive appearance of skin lesions. The virus is transmitted by close contact with lesions, body fluids, respiratory droplets and contaminated materials such as bedding. The disease is endemic in certain parts of West and Central Africa, but outbreaks can occur in non-endemic countries.
For more information about Monkeypox:
JYNNEOS® (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) suspension for subcutaneous injection is approved for the prevention of smallpox and monkeypox disease in adults 18 years of age and older determined to be at high risk for smallpox or monkeypox infection.1
JYNNEOS® was approved by the FDA in 2019 and is the only vaccine approved in the U.S. for the prevention of monkeypox. The vaccine is also approved in Canada for the prevention of smallpox and monkeypox and in Europe for immunization against smallpox. Bavarian Nordic has ongoing supply contracts with the governments of the United States and Canada and has delivered the vaccine to several governments globally as part of their national biological preparedness efforts.
Bavarian Nordic, headquartered in Denmark, is a fully integrated vaccines company focused on the development, manufacturing, and commercialization of vaccines to prevent and treat infectious diseases and cancers.
JYNNEOS® was developed under a long-standing collaboration with the U.S. government on medical countermeasures. Bavarian Nordic has ongoing supply contracts with the governments of the United States and Canada and has delivered the vaccine to several governments globally as part of their national biological preparedness efforts.
To learn more about Bavarian Nordic, and our portfolio of marketed and investigational vaccines, please visit our corporate website www.bavarian-nordic.com.
Clinician Outreach and Communication Activity (COCA) Calls/Webinars (including information devoted specifically to Monkeypox)
1. JYNNEOS® Prescribing information, Click Here to view accessed October 10, 2023.